Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neglecting Plasma Protein Binding in COVID-19 Patients Leads to a Wrong Interpretation of Lopinavir Overexposure.
Stanke-Labesque F, Concordet D, Djerada Z, Bouchet S, Solas C, Mériglier E, Bonnet F, Mourvillier B, Ruiz S, Martin-Blondel G, Epaulard O, Schwebel C, Gautier-Veyret E, Gandia P. Stanke-Labesque F, et al. Among authors: solas c. Clin Pharmacol Ther. 2021 Apr;109(4):1030-1033. doi: 10.1002/cpt.2196. Epub 2021 Mar 9. Clin Pharmacol Ther. 2021. PMID: 33547636 Free PMC article.
[Evidence-based therapeutic drug monitoring for ribavirine].
Solas C, Paré M, Quaranta S, Stanke-Labesque F; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique. Solas C, et al. Therapie. 2011 May-Jun;66(3):221-30. doi: 10.2515/therapie/2011036. Epub 2011 Aug 9. Therapie. 2011. PMID: 21819806 Review. French.
Niveau de preuve du suivi therapeutique pharmacologique de la ribavirine.
Solas C, Paré M, Quaranta S, Stanke-Labesque F; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Francaise de Pharmacologie et de Thérapeutique. Solas C, et al. Therapie. 2011 May-Jun;66(3):221-30. doi: 10.2515/therapie/2011036. Therapie. 2011. PMID: 27393202 French.
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2.
Eloy P, Solas C, Touret F, Mentré F, Malvy D, de Lamballerie X, Guedj J. Eloy P, et al. Among authors: solas c. Clin Pharmacol Ther. 2020 Aug;108(2):188. doi: 10.1002/cpt.1877. Epub 2020 May 21. Clin Pharmacol Ther. 2020. PMID: 32350860 No abstract available.
Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
Néant N, Lê MP, Bouazza N, Gattacceca F, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C. Néant N, et al. Among authors: solas c. Br J Clin Pharmacol. 2020 Dec;86(12):2404-2413. doi: 10.1111/bcp.14344. Epub 2020 Jun 1. Br J Clin Pharmacol. 2020. PMID: 32374049 Free PMC article.
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
Lemaitre F, Solas C, Grégoire M, Lagarce L, Elens L, Polard E, Saint-Salvi B, Sommet A, Tod M, Barin-Le Guellec C; French Society of Pharmacology, Therapeutics (SFPT), the International Association of Therapeutic Drug Monitoring, Clinical Toxicology (IATDMCT). Lemaitre F, et al. Among authors: solas c. Fundam Clin Pharmacol. 2020 Oct;34(5):530-547. doi: 10.1111/fcp.12586. Epub 2020 Jul 24. Fundam Clin Pharmacol. 2020. PMID: 32603486 Free PMC article. Review.
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
Venisse N, Peytavin G, Bouchet S, Gagnieu MC, Garraffo R, Guilhaumou R, Solas C; ANRS-AC43 Clinical Pharmacology Committee, SFPT Therapeutic Drug Monitoring and Treatment Personalization group. Venisse N, et al. Among authors: solas c. Antiviral Res. 2020 Sep;181:104866. doi: 10.1016/j.antiviral.2020.104866. Epub 2020 Jul 10. Antiviral Res. 2020. PMID: 32659293 Free PMC article. Review.
Kaposi's Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition.
Palich R, Makinson A, Veyri M, Guihot A, Valantin MA, Brégigeon-Ronot S, Poizot-Martin I, Solas C, Grabar S, Martin-Blondel G, Spano JP. Palich R, et al. Among authors: solas c. Cancers (Basel). 2021 Nov 15;13(22):5702. doi: 10.3390/cancers13225702. Cancers (Basel). 2021. PMID: 34830857 Free PMC article. Review.
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).
Lemaitre F, Grégoire M, Monchaud C, Bouchet S, Saint-Salvi B, Polard E; SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT); French Pharmacovigilance Network (CRPV); ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group; SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT); French Pharmacovigilance Network (CRPV); ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group. Lemaitre F, et al. Therapie. 2022 Sep-Oct;77(5):509-521. doi: 10.1016/j.therap.2022.03.005. Epub 2022 Apr 20. Therapie. 2022. PMID: 35618549 Free PMC article.
Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
Benaboud S, Solas C, Bouchet S, Gregoire M, Lemaitre F, Venisse N, Lê MP, Muret P, Parant F, Neant N, Boujafaar S, Lagoutte-Renosi J, Garraffo R, Peytavin G. Benaboud S, et al. Among authors: solas c. J Antimicrob Chemother. 2023 Mar 2;78(3):853-854. doi: 10.1093/jac/dkad009. J Antimicrob Chemother. 2023. PMID: 36683308 No abstract available.
145 results